ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type

Leukemia Research

Volumn 37, Issue 1, 2013, Pages 3-8

  Boelens, Jerina ^a   Jais, Jean Philippe ^b   Vanhoecke, Barbara ^a   Beck, Ilse ^a   Van Melckebeke, Heleen ^a   Philippé, Jan ^a   Bracke, Marc ^a   Jardin, Fabrice ^c   Brière, Josette ^d   Leroy, Karen ^e   Offner, Fritz ^a   Lust, Sofie ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c CENTRE HENRI BECQUEREL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

Author keywords

DLBCL; GRP94; UPR

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ACTIVATING TRANSCRIPTION FACTOR 6; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BREFELDIN A; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLUCOSE REGULATED PROTEIN 94; HEAT SHOCK PROTEIN 70; INITIATION FACTOR 2ALPHA; PREDNISONE; RITUXIMAB; STAUROSPORINE; THAPSIGARGIN; TUNICAMYCIN; VINCRISTINE; X BOX BINDING PROTEIN 1;

ACTIVATED B CELL LIKE DIFFUSE LARGE B CELL LYMPHOMA; ARTICLE; CANCER PROGNOSIS; CELL DEATH; CLINICAL TRIAL (TOPIC); ENDOPLASMIC RETICULUM STRESS; EVENT FREE SURVIVAL; GENE EXPRESSION; GERMINAL CENTER B CELL LIKE DIFFUSE LARGE B CELL LYMPHOMA; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENDOPLASMIC RETICULUM STRESS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MEMBRANE GLYCOPROTEINS; PREDNISONE; TUMOR MARKERS, BIOLOGICAL; UNFOLDED PROTEIN RESPONSE; VINCRISTINE;

EID: 84870911687     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.017     Document Type: Article

References (45)

1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
2. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
3. Rosenwald A., Wright G., Leroy K., Yu X., Gaulard P., Gascoyne R.D., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198:851-862.
4. Savage K.J., Monti S., Kutok J.L., Cattoretti G., Neuberg D., De Leval L., et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102:3871-3879.
5. Wright G., Tan B., Rosenwald A., Hurt E.H., Wiestner A., Staudt L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003, 100:9991-9996.
6. Mounier N., Brière J., Gisselbrecht C., Emile J.-F., Lederlin P., Sebban C., et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma. Blood 2003, 101:4279-4284.
7. Coiffier B., Lepage E., Brière J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
8. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
9. Gutierrez-García G., Cardessa-Salzmann T., Climent F., González-Barca E., Mercadal S., Mate J.L., et al. Gene-expression profiling and not-immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011, 117:4836-4843.
10. Van Anken E. I Braakman. Endoplasmic reticulum stress and the making of a professional secretory cell. Crit Rev Biochem Mol Biol 2005, 40:269-283.
11. Boelens J., Lust S., Offner F., Bracke M., Vanhoecke B. The endoplasmic reticulum: a target for new anticancer drugs. In Vivo 2007, 21:215-226.
12. Hendershot L.M., The ER function BiP is a master regulator of ER function. Mt Sinai J Med 2004, 71:289-297.
13. Schroder M., Kaufman R.J. The mammalian unfolded protein response. Annu Rev Biochem 2005, 74:739-789.
14. Szegezdi E., Logue S.E., Gorman A.M., Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 2006, 7:880-885.
15. Gass J.N., Gifford N.M., Brewer J.W. Activation of an unfolded protein response during differentiation of antibody-secreting B cells. J Biol Chem 2002, 277:49047-49054.
16. Nakamura M., Gotoh T., Okuno Y., Tatetsu H., Sonoki T., Uneda S., et al. Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells. Leuk Lymphoma 2006, 47:531-539.
17. Shapiro-Shelef M., Calame K. Plasma cell differentiation and multiple myeloma. Curr Opin Immunol 2004, 16:226-234.
18. Shaffer A.L., Rosenwald A., Staudt L.M. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002, 2:920-933.
19. Jais J.-P., Haioun C., Molina T.J., Rickman D.S., De Reynies A., Berger F., et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008, 22:1917-1924.
20. Monti S., Savaga K.J., Kutok J.L., Feuerhake F., Kurtin P., Mihm M., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005, 105:1851-1861.
21. Chou TC The median-effect principle and the combination index for quantitation of synergism and antagonism. Synergism and antagonism in chemotherapy 1991, 61-102. Academic Press, San Diego. T.C. Chou, D. Rideout (Eds.).
22. Lust S., Vanhoecke B., Janssens A., Philippé J., Bracke M., Offner F. Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res 2005, 49:844-850.
23. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Fermé C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
24. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80.
25. R Development Core Team R: a language and environment for statistical computing 2007, R Foundation for statistical computing, Vienna, Austria.
26. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data 2002, vol. 2. Jonn Wiley & Sons, Inc., Hoboken, New Jersey.
27. Maestre L., Tooze R., Canamero M., Montes-Moreno S., Ramos R., Doody G., et al. Expression pattern of XBP1(S) in human B-cell lymphomas. Haematologica 2009, 94:419-422.
28. Balague O., Mozos A., Martinez D., Hernandez L., Colome L., Mate J.L., et al. Activation of the endoplasmic reticulum stress-associated transcription factor x box-binding protein-1 occurs in a subset of normal germinal-center B cells and in aggressive B-cell lymphomas with prognostic implications. Am J Pathol 2009, 174:2337-2346.
29. Davenport E.L., Morgan G.J., Davies F.E. Untangling the unfolded protein response. Cell Cycle 2008, 7:865-869.
30. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
31. Rimsza L.M., Wright G., Schwartz M., Chan W.C., Jaffe E.S., Gascoyne R.D., et al. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. Clin Cancer Res 2011, 17:3727-3732.
32. Davenport E.L., Moore H.E., Dunlop A.S., Sharp S.Y., Workman P., Morgan G.J., et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007, 110:2641-2649.
33. Mozos A., Roue G., López-Guillermo, Jares P., Campo E., Colomer D., et al. The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large B-cell lymphoma. Am J Pathol 2011, 179:2601-2610.
34. Wang Q., He Z., Zhang J., Wang Y., Wang T., Tong S., et al. Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance. Cancer Detect Prev 2005, 29:544-551.
35. Gazit G., Lu J., Lee A.S. De-regulation of GRP stress protein expression in human breast cancer cell lines. Breast Cancer Res Treat 1999, 54:135-146.
36. Wang X.P., Qiu F.R., Liu G.Z., Chen R.F. Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma. World J Gastroenterol 2005, 11:1056-1059.
37. Zheng H.C., Takahashi H., Li X.H., Hara T., Masuda S., Guan Y., et al. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum Pathol 2008, 39:1042-1049.
38. Nomura H., Uzawa K., Yamano Y., Fushimi K., Ishigami T., Kato Y., et al. Network-based analysis of calcium-binding protein genes identifies Grp94 as a target in human oral carcinogenesis. Br J Cancer 2007, 97:792-801.
39. Kubota H., Suzuki T., Lu J., Takahashi S., Suqita K., Sekiya S., et al. Increased expression of GRP94 protein is associated with decreased sensitivity to X-rays in cervical cancer cell lines. Int J Radiat Biol 2005, 81:701-709.
40. Langer R., Feith M., Siewert J.R., Wester H.J., Hoefler H. Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer 2008, 8:70.
41. Staron M., Yang Y., Liu B., Li J., Shen Y., Zúniga-Pflücker J.C., et al. gp96, an endoplasmic reticulum master chaperone for integrins and Toll-like receptors, selectively regulates early T and B lymphopoiesis. Blood 2010, 115:2380-2390.
42. Zhang K., Wong H.N., Song B., Miller C.N., Scheuner D., Kaufman R.J. The unfolded protein response sensor IRE1α is required at 2 distinct steps in B cell lymphopoiesis. J Clin Invest 2005, 115:268-281.
43. Liu B., Li Z. Endoplasmic reticulum HSP90b1 (gp96, grp94) optimizes B-cell function via chaperoning integrin and TLR but not immunoglobulin. Blood 2008, 112:1223-1230.
44. Luo B., Lam B.S., Lee S.H., Wey S., Zhou H., Wang M., et al. The endoplasmic reticulum chaperone protein GRP94 is required for maintaining hematopoietic stem cell interactions with the adult bone marrow niche. PLOS One 2011, 6:e20364.
45. McLaughlin M., Vandenbroeck K. The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?. Br J Pharmacol 2011, 162:245-328.